SYRE Stock Forecast & Price Target

Spyre Therapeutics is viewed positively because its three in-house mechanisms—anti-α4β7, anti-TL1A, and anti-IL-23—have now generated a coherent clinical proof-of-concept in moderately-to-severely active ulcerative colitis, with SPY003 delivering a statistically significant 10.0-point RHI improvement at Week 12, 20% clinical remission, 30% endoscopic improvement, and no drug-related SAEs or discontinuations among 44 treated patients through Week 12. The investment case is further strengthened by the platform’s differentiation in convenience and manufacturability, since the mAbs are described as tailored for coformulation with potential Q3M or Q6M dosing via autoinjector, which could support adherence and commercial positioning versus multi-product regimens with more frequent dosing. Beyond IBD, SPY072 has already shown proof-of-mechanism in rheumatoid arthritis with complete and durable free-TL1A suppression through 12wk and a clean safety profile, while the large unmet-need opportunities in PsA, axSpA, and hidradenitis suppurativa expand the addressable market and create additional shots on goal as SKYLINE Part B results are expected in 2027 and SKYWAY PsA and axSpA data are expected in 4Q26.

Spyre Therapeutics is viewed negatively because, despite promising science, the company remains highly exposed to regulatory risk as accelerated approval paths may still require additional or longer studies, and any failure to secure differentiated labels could materially limit commercial traction. The pipeline’s early clinical signal is not yet enough to offset execution risk: SPY003 showed a clean safety profile but still had adverse events in 43% of patients, 11% Grade ≥3 AEs that were not drug-related, and only one drug-related AE, underscoring that efficacy and durability still need to be proven across its α4β7, TL1A, and IL-23 programs and combinations. Although Spyre is alone in having in-house anti-α4β7, anti-TL1A, and anti-IL-23 therapies and has expanded into rheumatology and dermatology, these are still development-stage assets in large but difficult indications where approved and late-stage drugs help only a modest fraction of patients, so the path to meaningful value creation remains uncertain and dependent on unproven combination success.